全文获取类型
收费全文 | 81篇 |
免费 | 6篇 |
专业分类
基础医学 | 18篇 |
口腔科学 | 1篇 |
内科学 | 47篇 |
皮肤病学 | 1篇 |
外科学 | 2篇 |
综合类 | 1篇 |
眼科学 | 2篇 |
肿瘤学 | 15篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 3篇 |
2019年 | 9篇 |
2018年 | 7篇 |
2017年 | 3篇 |
2015年 | 4篇 |
2014年 | 1篇 |
2013年 | 6篇 |
2012年 | 11篇 |
2011年 | 4篇 |
2010年 | 3篇 |
2009年 | 3篇 |
2008年 | 3篇 |
2007年 | 1篇 |
2006年 | 1篇 |
2005年 | 2篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2002年 | 5篇 |
2001年 | 1篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
排序方式: 共有87条查询结果,搜索用时 15 毫秒
51.
Giorgia Battipaglia MD PhD Myriam Labopin MD Rose-Marie Hamladji MD Didier Blaise MD Patrice Chevallier MD Eolia Brissot MD PhD Armin Gerbitz MD Gerard Socié MD Boris Afanasyev MD Fabio Ciceri MD PhD Ellen Meijer MD Yener Koc MD Jan J. Cornelissen MD Anne Huynh MD Hakan Ozdogu MD Johan Maertens MD Franciane Paul MD Hélène Labussière-Wallet MD Annalisa Ruggeri MD PhD Mahmoud Aljurf MD Ali Bazarbachi MD Bipin Savani MD Arnon Nagler MD PhD Mohamad Mohty MD PhD 《Cancer》2021,127(2):209-218
52.
Kristjan Paulson Ruta Brazauskas Nandita Khera Naya He Navneet Majhail Gorgun Akpek Mahmoud Aljurf David Buchbinder Linda Burns Sara Beattie Cesar Freytes Anne Garcia James Gajewski Theresa Hahn Jennifer Knight Charles LeMaistre Hillard Lazarus David Szwajcer Wael Saber 《Biology of blood and marrow transplantation》2019,25(10):2086-2090
Allogeneic hematopoietic cell transplantation (alloHCT) is offered in a limited number of medical centers and is associated with significant direct and indirect costs. The degree to which social and geographic barriers reduce access to alloHCT is unknown. Data from the Surveillance, Epidemiology and End Results Program (SEER) and the Center for International Blood and Marrow Transplant Research (CIBMTR) were integrated to determine the rate of unrelated donor (URD) alloHCT for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) performed between 2000 and 2010 in the 612 counties covered by SEER. The total incidence of AML, ALL, and MDS was determined using SEER, and the number of alloHCTs performed in the same time period and geographic area were determined using the CIBMTR database. We then determined which sociodemographic attributes influenced the rate of alloHCT (rural/urban status, median family size, percentage of residents below the poverty line, and percentage of minority race). In the entire cohort, higher levels of poverty were associated with lower rates of alloHCT (estimated rate ratio [ERR], .86 for a 10% increase in the percentage of the population below the poverty line; P < .01), whereas rural location was not (ERR, .87; P = .11). Thus, patients from areas with higher poverty rates diagnosed with ALL, AML, and MDS are less likely patients from wealthier counties to undergo URD alloHCT. There is need to better understand the reasons for this disparity and to encourage policy and advocacy efforts to improve access to medical care for all. 相似文献
53.
Brian T. Hill Kwang Woo Ahn Zhen-Huan Hu Mahmoud Aljurf Amer Beitinjaneh Jean-Yves Cahn Jan Cerny Mohamed A. Kharfan-Dabaja Siddhartha Ganguly Nilanjan Ghosh Michael R. Grunwald Yoshihiro Inamoto Tamila Kindwall-Keller Taiga Nishihori Richard F. Olsson Ayman Saad Matthew Seftel Sachiko Seo Wael Saber 《Biology of blood and marrow transplantation》2018,24(3):581-586
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the only known curative treatment for CLL. The potential benefit of transplantation is most likely due to the presence of alloreactive donor T cells that mediate the graft-versus-leukemia (GVL) effect. The recognition of potentially tumor-specific antigens in the context of class I and II major histocompatibility complex on malignant B lymphocytes by donor T cells may be influenced by subtle differences in the highly polymorphic HLA locus. Given previous reports of specific HLA alleles impacting the incidence of CLL and the clinical outcomes of allo-HCT for CLL, we sought to study the overall survival and progression-free survival of a large cohort of patients with CLL who underwent allo-HCT from fully HLA-matched related and unrelated donors at Center for International Blood and Marrow Transplant Research transplantation centers. We found no statistically significant association of allo-HCT outcomes in CLL based on previously reported HLA combinations. Additional study is needed to further define the immunologic features that portend a more favorable GVL effect after allo-HCT for CLL. 相似文献
54.
The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time
Ruah AlYamany Mohamed A. Kharfan-Dabaja Mehdi Hamadani Alfadel Alshaibani Mahmoud Aljurf 《Current oncology (Toronto, Ont.)》2022,29(5):3759
Immunoproliferative small intestinal disease (IPSID) is an uncommon disease with a higher prevalence in the developing world. IPSID diagnosis relies mainly on a tissue biopsy and a high index of suspicion. Treatment options are variable; however, they mainly include anthracycline-based chemotherapy with or without antibiotics in advanced stages. Because of the paucity of IPSID, our perception of the disease remains narrow, and investigating the optimal lines of therapy and prevention without a complete comprehension of the disease is challenging. In our review, we explore the expansion of knowledge about IPSID, which has been developing over the years, to help increase the detection of IPISD cases and further research the most appropriate lines of therapy and prevention. 相似文献
55.
Ballen KK Woolfrey AE Zhu X Ahn KW Wirk B Arora M George B Savani BN Bolwell B Porter DL Copelan E Hale G Schouten HC Lewis I Cahn JY Halter J Cortes J Kalaycio ME Antin J Aljurf MD Carabasi MH Hamadani M McCarthy P Pavletic S Gupta V Deeg HJ Maziarz RT Horowitz MM Saber W 《Biology of blood and marrow transplantation》2012,18(9):1446-1454
Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splenectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ET and PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS. 相似文献
56.
Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved over the past two decades to become the standard of care for hematologic and lymphoid malignancies. Major ocular complications after allogeneic HSCT have been increasing in number and severity. Graft-versus-host disease (GVHD) remains a major cause of ocular morbidity after allogeneic HSCT. The main objective of this review is to elucidate the ocular complications in patients developing GVHD following HSCT.Ocular complications secondary to GVHD are common and include dry eye syndrome, acquisition of ocular allergy from donors with allergic disorders. Eyelid changes may occur in GVHD leading to scleroderma-like changes. Patients may develop poliosis, madarosis, vitiligo, lagophthalmos, and entropion. The cornea may show filamentary keratitis, superficial punctate keratitis, corneal ulcers, and peripheral corneal melting which may lead to perforation in severe cases. Scleritis may also occur which can be anterior or posterior. Keratoconjunctivis sicca appears to be the most common presentation of GVHD. The lacrimal glands may be involved with mononuclear cell infiltration of both the major and accessory lacrimal glands and decrease in tear production.Severe dry eye syndrome in patients with GVHD may develop conjunctival scarring, keratinization, and cicatrization of the conjunctiva.Therapy of GVHD includes systemic immunosuppression and local therapy. Surgical treatment in refractory cases includes surgical intervention to improve the manifestation of GVHD of the eye. This may include tarsorrhapy, prose lenses, punctal occlusions and corneal transplantation. 相似文献
57.
Al Beihany A Al Mohareb F Al Zahrani H Alsharif F Chaudhri N Mohamed SY Rasheed W Aljurf M 《Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation》2011,9(6):432-433
We describe a pattern of relapse in 601 patients who received an allogeneic hematopoietic stem cell transplant at our institution for acute or chronic leukemia and myelodysplasia over a period of 18 years. We show a correlation between chronic graft-versus-host disease and extramedullary relapse, suggesting that the expected graft versus leukemia effect in patients with chronic graft-versus-host disease may preferentially maintain marrow remission without preventing relapse in extramedullary sites. 相似文献
58.
Ibrahim K Maghfoor I Elghazaly A Bakshi N Mohamed SY Aljurf M 《Hematology/oncology and stem cell therapy》2011,4(2):100-102
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder of incompletely understood etiology and with various clinical presentations. The best therapeutic option for this disease is not well established. MCD is known to be associated with autoimmune phenomena. A 70-year-old female patient of MCD with progressive nodal disease associated with autoimmune thrombocytopenia failed steroid treatment and showed a transient response to intravenous immunoglobulin. The patient achieved complete recovery of her platelet count and a very good response in nodal disease after 3 weekly doses of anti-CD-20 antibody (rituximab). Anti-CD20 antibody treatment could be a good therapeutic option for MCD, mainly when associated with immune-related disorders. 相似文献
59.
Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party,Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT 下载免费PDF全文
Carlo Dufour Paul Veys Elisa Carraro Neha Bhatnagar Marta Pillon Rob Wynn Brenda Gibson Ajay J. Vora Colin G. Steward Anna M. Ewins Rachael E. Hough Josu de la Fuente Mark Velangi Persis J. Amrolia Roderick Skinner Andrea Bacigalupo Antonio M. Risitano Gerard Socie Regis Peffault de Latour Jakob Passweg Alicia Rovo André Tichelli Hubert Schrezenmeier Britta Hochsmann Peter Bader Anja van Biezen Mahmoud D. Aljurf Austin Kulasekararaj Judith C. Marsh Sujith Samarasinghe 《British journal of haematology》2015,171(4):585-594
We explored the feasibility of unrelated donor haematopoietic stem cell transplant (HSCT) upfront without prior immunosuppressive therapy (IST) in paediatric idiopathic severe aplastic anaemia (SAA). This cohort was then compared to matched historical controls who had undergone first‐line therapy with a matched sibling/family donor (MSD) HSCT (n = 87) or IST with horse antithymocyte globulin and ciclosporin (n = 58) or second‐line therapy with unrelated donor HSCT post‐failed IST (n = 24). The 2‐year overall survival in the upfront cohort was 96 ± 4% compared to 91 ± 3% in the MSD controls (P = 0·30) and 94 ± 3% in the IST controls (P = 0·68) and 74 ± 9% in the unrelated donor HSCT post‐IST failure controls (P = 0·02).The 2‐year event‐free survival in the upfront cohort was 92 ± 5% compared to 87 ± 4% in MSD controls (P = 0·37), 40 ± 7% in IST controls (P = 0·0001) and 74 ± 9% in the unrelated donor HSCT post‐IST failure controls (n = 24) (P = 0·02). Outcomes for upfront‐unrelated donor HSCT in paediatric idiopathic SAA were similar to MSD HSCT and superior to IST and unrelated donor HSCT post‐IST failure. Front‐line therapy with matched unrelated donor HSCT is a novel treatment approach and could be considered as first‐line therapy in selected paediatric patients who lack a MSD. 相似文献
60.
Eolia Brissot Myriam Labopin Marielle M. Beckers Gérard Socié Alessandro Rambaldi Liisa Volin Jürgen Finke Stig Lenhoff Nicolaus Kr?ger Gert J. Ossenkoppele Charles F. Craddock Ibrahim Yakoub-Agha Günhan Gürman Nigel H. Russell Mahmoud Aljurf Michael N. Potter Armon Nagler Oliver Ottmann Jan J. Cornelissen Jordi Esteve Mohamad Mohty 《Haematologica》2015,100(3):392-399
This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting. 相似文献